A recently published retrospective study evaluated the All-on-4® treatment concept in 152 patients with Brånemark System MkIII and MkIV implants placed from May 2005 until December 2011. CSR was 96.3% and 97.8% at one and at five years in the maxilla (300 implants) and the mandible (500 implants), respectively.
Sub-analyses by tilted vs. axial placement and by gender showed no difference or no significant difference. Implant failures were higher in smokers than non-smokers (6.1% vs. 2.1%); however, likely due to low failure rates overall, statistical significance was not reported. The authors discussed the improvements in CSR witnessed in the published literature over time with the All-on-4® treatment concept and attributed these successes to the introduction of TiUnite surface implants.